본문으로 건너뛰기
← 뒤로

Microwave-assisted one-pot green synthesis, ADMET profiling, DFT, and molecular docking of novel 3-cyano-2-pyridone derivatives as dual EGFR and cytokine (TNF-α, IL-6) inhibitors.

European journal of medicinal chemistry 2025 Vol.300() p. 118165

Lotfy EM, Bokhtia RM, Abdel Fattah HA, Seliem IA

📝 환자 설명용 한 줄

Epidermal Growth Factor Receptor (EGFR) is crucial for cancer cell growth, survival, and resistance.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Lotfy EM, Bokhtia RM, et al. (2025). Microwave-assisted one-pot green synthesis, ADMET profiling, DFT, and molecular docking of novel 3-cyano-2-pyridone derivatives as dual EGFR and cytokine (TNF-α, IL-6) inhibitors.. European journal of medicinal chemistry, 300, 118165. https://doi.org/10.1016/j.ejmech.2025.118165
MLA Lotfy EM, et al.. "Microwave-assisted one-pot green synthesis, ADMET profiling, DFT, and molecular docking of novel 3-cyano-2-pyridone derivatives as dual EGFR and cytokine (TNF-α, IL-6) inhibitors.." European journal of medicinal chemistry, vol. 300, 2025, pp. 118165.
PMID 40975960

Abstract

Epidermal Growth Factor Receptor (EGFR) is crucial for cancer cell growth, survival, and resistance. Inflammatory cytokines like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) also help tumors grow and evade the immune system. Developing multi-targeted inhibitors that hit both cancerous and inflammatory pathways has strong therapeutic potential. This study aims to design, create, and test novel series of pyridone-based derivatives serving as dual inhibitors of EGFR signaling pathways with anti-inflammatory effects by suppressing IL-6 and TNF-α. We synthesized and structurally characterized a set of novel pyridone derivatives. We checked their physicochemical and pharmacokinetic properties using in silico ADMET profiling. We evaluated the anticancer activity of the compounds through the MTT assay, testing viability and cytotoxicity in MCF-7 (breast) and A549 (lung) cancer cell lines. We further assessed selected compounds for their EGFR inhibitory effects and cytokine suppression. We conducted flow cytometry (Annexin V/PI staining) to evaluate apoptosis induction. Some of the novel compounds showed high binding affinity to EGFR in docking studies. Among these, compound 5h showed potent anticancer activity on both tested cell lines A549 and MCF7 with an IC of 9.2 μM and 8.2 μM respectively also it significantly reduced IL-6 and TNF-α levels in A549 cells, also showed promising ADMET profiles. Flow cytometry confirmed apoptosis induction in a dose-dependent manner. We performed molecular docking to evaluate the binding affinity against EGFR and related inflammatory targets. DFT calculations were performed to analyze molecular reactivity through HOMO/LUMO and molecular electrostatic potential (ESP) studies. ESP map analysis supports theoretical descriptors and confirms that compound 5h is the most biologically active candidate among the synthesized derivatives.

MeSH Terms

Humans; ErbB Receptors; Molecular Docking Simulation; Interleukin-6; Tumor Necrosis Factor-alpha; Antineoplastic Agents; Molecular Structure; Pyridones; Structure-Activity Relationship; Microwaves; Drug Screening Assays, Antitumor; Cell Proliferation; Dose-Response Relationship, Drug; Density Functional Theory; Green Chemistry Technology; Apoptosis; Protein Kinase Inhibitors; Cell Survival; Interleukin-6 Inhibitors